Treatment effects of stimulant medication in young boys with fragile X syndrome

Journal of Neurodevelopmental Disorders

Volumn 3, Issue 3, 2011, Pages 175-184

  Roberts, Jane E ^a   Miranda, Margot ^b   Boccia, Maria ^c   Janes, Heather ^b   Tonnsen, Bridgette L ^a   Hatton, Deborah D ^d  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c Gordon Conwell Theological Seminary   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

FMR1; Fragile X; Medication; Mental retardation; Stimulants

Indexed keywords

EID: 80052373908     PISSN: 18661947     EISSN: 18661955     Source Type: Journal    
DOI: 10.1007/s11689-011-9085-4     Document Type: Article

References (62)

1. Achenbach TM. Manual for the child behavior checklist/4-18 and 1991 profile. Burlington, VT: University of Vermont Department of Psychiatry; 1991.
2. Achenbach TM, Rescorla LA. Manual for the ASEBA school-age forms and profiles. Burlington, VT: University of Vermont, Research Center for Children, Youth, and Families; 2001.
3. Aman MG, Pejeau C, Osborne P, Rojahn J, Handen B. Four-year follow-up of children with low intelligence and ADHD. Res Dev Disabil. 1996; 17(6): 417-32.
4. Aman MG, Buican B, Arnold LE. Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies. J Child Adolesc Psychopharmacol. 2003; 13(1): 29-40.
5. Amaría RN, Billeisen LL, Hagerman RJ. Medication use in fragile X syndrome. Ment Health Aspect Dev Disabil. 2001; 4: 143-7.
6. Backes M, Genc B, Schreck J, Doerfler W, Lehmkuhl G, von Gontard A. Cognitive and behavioral profile of fragile X boys: correlations to molecular data. Am J Med Genet. 2000; 95(2): 150-6.
7. Bailey Jr DB, Hatton DD, Skinner M. Early developmental trajectories of males with fragile X syndrome. Am J Ment Retard. 1998; 103(1): 29-39.
8. Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990; 86(2): 184-92.
9. Baumgardner TL, Reiss AL, Freund LS, Abrams MT. Specification of the neurobehavioral phenotype in males with fragile X syndrome. Pediatrics. 1995; 95(5): 744-52.
10. Berry-Kravis E, Potanos K. Psychopharmacology in fragile X syndrome-present and future. Ment Retard Dev Disabil Res Rev. 2004; 10(1): 42-8.
11. Berry-Kravis E, Lewin F, Wuu J, Leehey M, Hagerman R, Hagerman P, et al. Tremor and ataxia in fragile X premutation carriers: blinded videotape study. Ann Neurol. 2003; 53(5): 616-23.
12. Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008; 29(4): 293-302.
13. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009; 46(4): 266-71.
14. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet. 2009; 46(2): 94-102.
15. Chen WJ, Faraone SV, Biederman J, Tsuang MT. Diagnostic accuracy of the Child Behavior Checklist scales for attention-deficit hyperactivity disorder: a receiver-operating characteristic analysis. J Consult Clin Psychol. 1994; 62(5): 1017-25.
16. Comery TA, Harris JB, Willems PJ, Oostra BA, Irwin SA, Weiler IJ, et al. Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci U S A. 1997; 94(10): 5401-4.
17. Ebesutani C, Bernstein A, Nakamura BJ, Chorpita BF, Higa-McMillan CK, Weisz JR. Concurrent validity of the Child Behavior Checklist DSM-Oriented Scales: correspondence with DSM Diagnoses and comparison to Syndrome Scales. J Psychopathol Behav Assess. 2010; 32(3): 373-84.
18. Erickson CA, Weng N, Weiler IJ, Greenough WT, Stigler KA, Wink LK, et al. Open-label Riluzole in fragile X syndrome. Brain Res. 2011; 22(1380): 264-70.
19. Freund LS, Reiss AL, Abrams MT. Psychiatric disorders associated with fragile X in the young female. Pediatrics. 1993; 91(2): 321-9.
20. Fryns JP. X-linked mental retardation. Medical genetics: past present, and future. New York: Liss; 1985. p. 309-19.
21. Hagerman RJ. Psychopharmacological interventions in fragile X syndrome, fetal alcohol syndrome, Prader-Willi syndrome, Angelman syndrome, Smith-Magenis syndrome, and velocardiofacial syndrome. Ment Retard Dev Disabil Res Rev. 1999; 5: 305-13.
22. Hagerman RJ. The physical and behavioral phenotype. In: Hagerman PJ, Hagerman AE, editors. Fragile X syndrome: diagnosis, treatment, and research. 3rd ed. Baltimore: Johns Hopkins University; 2002. p. 3-109.
23. Hagerman RJ, Murphy MA, Wittenberger MD. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet. 1988; 30(1-2): 377-92.
24. Hagerman RJ, Hull CE, Safanda JF, Carpenter I, Staley LW, O'Connor RA, et al. High functioning fragile X males: demonstration of an unmethylated fully expanded FMR-1 mutation associated with protein expression. Am J Med Genet. 1994; 51(4): 298-308.
25. Hagerman RJ, Miller LJ, McGrath-Clarke J, Riley K, Goldson E, Harris SW, et al. Influence of stimulants on electrodermal studies in fragile X syndrome. Microsc Res Tech. 2002; 57(3): 168-73.
26. Handen BL, Gilchrist R. Practitioner review: psychopharmacology in children and adolescents with mental retardation. J Child Psychol Psych. 2006; 47(9): 871-82.
27. Handen BL, Feldman HM, Lurier A, Murray PJ. Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD. J Am Acad Child Adolesc Psych. 1999; 38(7): 805-12.
28. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000; 30(3): 245-55.
29. Hayashi ML, Rao BS, Seo JS, Choi HS, Dolan BM, Choi SY, et al. Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proc Natl Acad Sci U S A. 2007; 104(27): 11489-94.
30. Hessl D, Dyer-Friedman J, Glaser B, Wisbeck J, Barajas RG, Taylor A, et al. The influence of environmental and genetic factors on behavior problems and autistic symptoms in boys and girls with fragile X syndrome. Pediatrics. 2001; 108(5): E88.
31. Kwon H, Menon V, Eliez S, Warsofsky IS, White CD, Dyer-Friedman J, et al. Functional neuroanatomy of visuospatial working memory in fragile X syndrome: relation to behavioral and molecular measures. Am J Psychiatry. 2001; 158(7): 1040-51.
32. Lawrence CA, Barry RJ, Clarke AR, Johnstone SJ, McCarthy R, Selikowitz M, et al. Methylphenidate effects in attention deficit/hyperactivity disorder: electrodermal and ERP measures during a continuous performance task. Psychopharmacology (Berl). 2005; 183(1): 81-91.
33. Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev. 2004; 10(1): 31-41.
34. Miller LJ, McIntosh DN, McGrath J, Shyu V, Lampe M, Taylor AK, et al. Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report. Am J Med Genet. 1999; 83(4): 268-79.
35. Mini Mitter Company 2000 W. Windows Version 1. 2 ed. Oregon2001.
36. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004; 113(4): 762-9.
37. Noldus Information Technology. The Observer, Computer software and manual. 5 ed. The Netherlands 2003.
38. Oades RD, Sadile AG, Sagvolden T, Viggiano D, Zuddas A, Devoto P, et al. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles. Dev Sci. 2005; 8(2): 122-31.
39. Ornstein PA, Schaaf JM, Hooper SR, Hatton DD, Mirrett P, Bailey DB Jr. Memory skills of boys with fragile X syndrome. Am J Ment Retard. 2008; 113(6): 453-65.
40. Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 2010; 10: 91.
41. Pearson DA, Lane DM, Santos CW, Casat CD, Jerger SW, Loveland KA, et al. Effects of methylphenidate treatment in children with mental retardation and ADHD: individual variation in medication response. J Am Acad Child Adolesc Psych. 2004; 43(6): 686-98.
42. Porges SW. MXedit V2. 21 Beta. Bethesda, MD: Delta Biometrics, Inc; 1994.
43. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005; 62(11): 1266-74.
44. Riley K, Ikle LO, Hagerman RJ. A randomized, double-blind comparative trial of Adderall in the treatment of attention deficit disorder in children with fragile X. 7th International Fragile X Conference; July 19-23; Los Angeles 2000.
45. Roberts JE, Boccia ML, Bailey Jr DB, Hatton DD, Skinner M. Cardiovascular indices of physiological arousal in boys with fragile X syndrome. Dev Psychobiol. 2001; 39(2): 107-23.
46. Roberts J, Mazzocco MM, Murphy MM, Hoehn-Saric R. Arousal modulation in females with fragile X or Turner syndrome. J Autism Dev Disord. 2008; 38(1): 20-7.
47. Roid GH, Miller LJ. Leiter International Performance Scale-revised. Wood Dale, IL: Stoelting Co; 1997.
48. Sattler JM. Assessment of academic achievement and special abilities. In Assessment of Children. 3rd ed. San Diego: Sattler; 1990.
49. Scahill L, Pachler M. Treatment of hyperactivity in children with pervasive developmental disorders. J Child Adolesc Psychiatr Nurs. 2007; 20(1): 59-62.
50. Staley-Gane L, Flynn L, Neitzel K, Cronister A, Hagerman RJ. Expanding the role of the genetic counselor. Am J Med Genet. 1996; 64(2): 382-7.
51. Sullivan K, Hatton D, Hammer J, Sideris J, Hooper S, Ornstein P, et al. ADHD symptoms in children with FXS. Am J Med Genet A. 2006; 140(21): 2275-88.
52. l-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A. 2008; 146(7): 803-12.
53. Torrioli M, Vernacotola S, Setini C, Bevilacqua F, Martinelli D, Snape M, et al. Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. Am J Med Genet A. 2010; 152A(6): 1420-7.
54. Tsiouris JA, Brown WT. Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy. CNS Drugs. 2004; 18(11): 687-703.
55. Turk J. The fragile-X syndrome. On the way to a behavioural phenotype. Br J Psychiatry. 1992; 160: 24-35.
56. Vaughan van Hecke A, Bal E, Lamb D, Harden E, Kramer A, Denver J, et al. Electroencephalogram and heart rate regulation to familiar and unfamiliar people in children with autism spectrum disorders. Child Development. 2009; 80(4): 1118-33.
57. Wang Y, Bowman D, Krum D, Coalho E, Smith-Jackson T, Bailey D, et al. Effects of video placement and spatial context presentation on path reconstruction tasks with contextualized videos. IEEE Trans Vis Comput Graph. 2008; 14(6): 1755-62.
58. Wang H, Kim SS, Zhuo M. Roles of fragile X mental retardation protein in dopaminergic stimulation-induced synapse-associated protein synthesis and subsequent alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) receptor internalization. J Biol Chem. 2010; 285(28): 1888-901.
59. Weiler IJ, Greenough WT. Synaptic synthesis of the fragile X protein: possible involvement in synapse maturation and elimination. Am J Med Genet. 1999; 83(4): 248-52.
60. Woodcock RW, Mather N. In: Johnson RWWMB, editor. Woodcock-Johnson Psycho-Educational Battery-revised. Itasca, IL: Riverside Pub; 1990.
61. Zeier ZKA, Bodhinathan K, Feller JA, Foster TC, Bloom DC. Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome. Gene Ther. 2009; 16(9): 1122-9.
62. Zentall SS, Zentall TR. Optimal stimulation: a model of disordered activity and performance in normal and deviant children. Psychol Bull. 1983; 94(3): 446-71.